• 1
    Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. and Kawaoka, Y., Evolution and ecology of influenza A viruses. Microbiol. Rev. 1992. 56: 152179.
  • 2
    Carrat, F. and Flahault, A., Influenza vaccine: the challenge of antigenic drift. Vaccine 2007. 25: 68526862.
  • 3
    Neumann, G., Chen, H., Gao, G. F., Shu, Y. and Kawaoka, Y., H5N1 influenza viruses: outbreaks and biological properties. Cell Res. 2010. 20: 5161.
  • 4
    Lopez, P., Caicedo, Y., Sierra, A., Tilman, S., Banzhoff, A. and Clemens, R., Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults. J. Infect. Dis. 2011. 203: 17191728.
  • 5
    Nicholson, K. G., Colegate, A. E., Podda, A., Stephenson, I., Wood, J., Ypma, E. and Zambon, M. C., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001. 357: 19371943.
  • 6
    Stephenson, I., Nicholson, K. G., Colegate, A., Podda, A., Wood, J., Ypma, E. and Zambon, M., Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003. 21: 16871693.
  • 7
    Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C. and Katz, J. M., Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis. 2005. 191: 12101215.
  • 8
    Atmar, R. L., Keitel, W. A., Patel, S. M., Katz, J. M., She, D., El, S. H., Pompey, J. et al., Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis. 2006. 43: 11351142.
  • 9
    Stephenson, I., Gust, I., Pervikov, Y. and Kieny, M. P., Development of vaccines against influenza H5. Lancet Infect. Dis. 2006. 6: 458460.
  • 10
    Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Drame, M., Clement, F., Hons, E., Devaster, J. M. et al., Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007. 370: 580589.
  • 11
    Gioia, C., Castilletti, C., Tempestilli, M., Piacentini, P., Bordi, L., Chiappini, R., Agrati, C. et al., Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg. Infect. Dis. 2008. 14: 121128.
  • 12
    Corti, D., Suguitan, A. L., Jr., Pinna, D., Silacci, C., Fernandez-Rodriguez, B. M., Vanzetta, F., Santos, C. et al., Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 2010. 120: 16631673.
  • 13
    Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L., Alard, P., Cornelissen, L., Bakker, A. et al., Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS. One 2008. 3: e3942.
  • 14
    Wrammert, J., Smith, K., Miller, J., Langley, W. A., Kokko, K., Larsen, C., Zheng, N. Y. et al., Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008. 453: 667671.
  • 15
    Wang, T. T., Tan, G. S., Hai, R., Pica, N., Petersen, E., Moran, T. M. and Palese, P., Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS. Pathog. 2010. 6: e1000796.
  • 16
    Ekiert, D. C., Friesen, R. H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C. et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011. 333: 843850.
  • 17
    Wrammert, J., Koutsonanos, D., Li, G. M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M. et al., Broadly cross-reactive antibodies dominate the human B-cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011. 208: 181193.
  • 18
    Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G. et al., A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011. 333: 850856.
  • 19
    Galli, G., Medini, D., Borgogni, E., Zedda, L., Bardelli, M., Malzone, C., Nuti, S. et al., Adjuvanted H5N1 vaccine induces early CD4+ T-cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 2009. 106: 38773882.
  • 20
    Alberini, I., Del Tordello, E., Fasolo, A., Temperton, N. J., Galli, G., Gentile, C., Montomoli, E. et al., Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 2009. 27: 59986003.
  • 21
    Bernstein, D. I., Edwards, K. M., Dekker, C. L., Belshe, R., Talbot, H. K., Graham, I. L., Noah, D. L. et al., Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 2008. 197: 66775.
  • 22
    Ekiert, D. C., Bhabha, G., Elsliger, M. A., Friesen, R. H., Jongeneelen, M., Throsby, M., Goudsmit, J. et al., Antibody recognition of a highly conserved influenza virus epitope. Science 2009. 324: 246251.
  • 23
    Khurana, S., Suguitan, A. L., Jr., Rivera, Y., Simmons, C. P., Lanzavecchia, A., Sallusto, F., Manischewitz, J. et al., Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS. Med. 2009. 6: e1000049.
  • 24
    Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L. R., Honorkiewicz, A., Rock, M. T. et al., Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2010. 2: 15ra5.
  • 25
    Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Del Giudice, G. et al., MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 2011. 3: 85ra48.